Microbot Medical Surges On Stryker Collaboration
By Sam Boughedda
Investing.com — Microbot Medical Inc (NASDAQ: MBOT ), the medical device firm, is up nearly 70% to $9.20 Monday morning on news it has inked a deal with Stryker Corporation (NYSE: SYK ), a medical technology company.
Massachusetts-based Microbot will collaborate with Stryker's Neurovascular unit to combine its neurovascular instruments with Microbot's LIBERTY Robotic System to create what they described as the world's first dedicated robotic procedural kits for use in neurovascular procedures.
Stryker shares are little moved following the news, up around 0.1%.
“We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space,” commented Harel Gadot, Chairman, CEO and President of Microbot Medical.
Gadot added that the deal will also allow them to accelerate their goal of "changing the way robotic surgery is viewed and adopted.”
Microbot said last week that it secured a third U.S. patent for the LIBERTY Robotic System. The company also told investors that it is searching for clinical sites to commence a human clinical trial.
They will continue developing the LIBERTY Robotic System independently for peripheral and coronary procedures.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.
Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or